Policy | September 16, 2025
FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
CRISPR-based detection enables highly specific molecular recognition
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Maria Soler Nunez appointed as Chief Quality Officer
Hemant Surgical Industries receives order
Subscribe To Our Newsletter & Stay Updated
